Avidity Biosciences (RNA) to Release Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $1.9820 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Avidity Biosciences Trading Down 0.0%

RNA stock opened at $72.83 on Thursday. The stock has a 50-day moving average price of $72.44 and a two-hundred day moving average price of $60.80. Avidity Biosciences has a 1 year low of $21.51 and a 1 year high of $73.06. The stock has a market cap of $11.27 billion, a PE ratio of -17.42 and a beta of 0.93.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on RNA shares. Wall Street Zen raised shares of Avidity Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Citigroup downgraded shares of Avidity Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, October 27th. Evercore set a $72.00 price target on shares of Avidity Biosciences in a research note on Thursday, December 18th. Wolfe Research downgraded shares of Avidity Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Finally, Roth Mkm cut Avidity Biosciences from a “strong-buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a report on Monday, October 27th. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $69.57.

Insider Buying and Selling

In related news, insider Steven George Hughes sold 4,895 shares of Avidity Biosciences stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $72.45, for a total transaction of $354,642.75. Following the completion of the sale, the insider owned 31,599 shares of the company’s stock, valued at approximately $2,289,347.55. The trade was a 13.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sarah Boyce sold 14,387 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $72.45, for a total value of $1,042,338.15. Following the sale, the chief executive officer owned 269,007 shares of the company’s stock, valued at approximately $19,489,557.15. This represents a 5.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 58,407 shares of company stock valued at $4,226,448. 3.83% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Avidity Biosciences

A number of large investors have recently modified their holdings of RNA. EFG International AG bought a new stake in shares of Avidity Biosciences during the 4th quarter worth $33,000. Smartleaf Asset Management LLC raised its stake in Avidity Biosciences by 426.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 397 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Avidity Biosciences in the fourth quarter worth about $34,000. Comerica Bank lifted its holdings in shares of Avidity Biosciences by 75.9% in the third quarter. Comerica Bank now owns 1,335 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 576 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of Avidity Biosciences by 1,659.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,543 shares in the last quarter.

Avidity Biosciences Company Profile

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.